Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581

Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581

Item
http://www.wikidata.org/entity/Q35170266
Redefining high-risk patients with stage II colon cancer by risk index and microRNA-21: results from a population-based cohortCirculating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer.Evaluation of relapse-free survival in T3N0 colon cancer: the role of chemotherapy, a multicentric retrospective analysis.Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer--a study of CALGB 9581 and 89803.The Globalization of Cooperative Groups.Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581.Expression of EpCAM(MF) and EpCAM(MT) variants in human carcinomas.Antibody-based therapy in colorectal cancer.Monoclonal antibodies against human cancer stem cells.Immune-based therapies in pancreatic and colorectal cancers and biomarkers of responsiveness.Nuclear factor of activated T-cell activity is associated with metastatic capacity in colon cancer.A Study of Thymidylate Synthase Expression as a Biomarker for Resectable Colon Cancer: Alliance (Cancer and Leukemia Group B) 9581 and 89803.Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance).Use of Ber-EP4 and Epithelial Specific Antigen to Differentiate Clinical Simulators of Basal Cell Carcinoma.Perineural Invasion is a Major Prognostic and Predictive Factor of Response to Adjuvant Chemotherapy in Stage I-II Colon Cancer.Loss of membranous expression of the intracellular domain of EpCAM is a frequent event and predicts poor survival in patients with pancreatic cancer.
P2860

Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581

Item
http://www.wikidata.org/entity/Q35170266
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Documenting the natural histor ...... ation: results from CALGB 9581
@ast
Documenting the natural histor ...... ation: results from CALGB 9581
@en
type
label
Documenting the natural histor ...... ation: results from CALGB 9581
@ast
Documenting the natural histor ...... ation: results from CALGB 9581
@en
prefLabel
Documenting the natural histor ...... ation: results from CALGB 9581
@ast
Documenting the natural histor ...... ation: results from CALGB 9581
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P577
P5875
P698
P921
P932
P356
P1433
P1476
Documenting the natural histor ...... ation: results from CALGB 9581
@en
P2093
P2860
P304
P31
P356
P407
P433
P478
P577
P5875
P698
P921
P932